These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12115018

  • 1. Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study.
    Pilotto A, Franceschi M, Leandro G, Novello R, Di Mario F, Valerio G.
    Am J Ther; 2002; 9(4):295-300. PubMed ID: 12115018
    [Abstract] [Full Text] [Related]

  • 2. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ, Salas M, Ward A.
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [Abstract] [Full Text] [Related]

  • 3. Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole.
    Pilotto A, Leandro G, Franceschi M, Ageing and Acid-Related Disease Study Group.
    Aliment Pharmacol Ther; 2003 Jun 01; 17(11):1399-406. PubMed ID: 12786634
    [Abstract] [Full Text] [Related]

  • 4. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
    Pilotto A, Perri F, Leandro G, Franceschi M, Aging and Acid-Related Disease Study Group.
    Gerontology; 2006 Jun 01; 52(2):99-106. PubMed ID: 16508317
    [Abstract] [Full Text] [Related]

  • 5. Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
    Calleja JL, Suarez M, De Tejada AH, Navarro A, Pantogerd Group.
    Dig Dis Sci; 2005 Mar 01; 50(3):432-9. PubMed ID: 15810621
    [Abstract] [Full Text] [Related]

  • 6. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
    Holtmann G, Cain C, Malfertheiner P.
    Gastroenterology; 1999 Jul 01; 117(1):11-6. PubMed ID: 10381904
    [Abstract] [Full Text] [Related]

  • 7. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A, Franceschi M, Leandro G, Scarcelli C, D'Ambrosio LP, Paris F, Annese V, Seripa D, Andriulli A, Di Mario F.
    World J Gastroenterol; 2007 Sep 07; 13(33):4467-72. PubMed ID: 17724802
    [Abstract] [Full Text] [Related]

  • 8. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D, Paré P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group.
    Am J Gastroenterol; 2001 Oct 07; 96(10):2849-57. PubMed ID: 11695354
    [Abstract] [Full Text] [Related]

  • 9. Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
    Dupas JL, Houcke P, Samoyeau R, French Collaborative Pantaprazole Study Group.
    Gastroenterol Clin Biol; 2001 Mar 07; 25(3):245-50. PubMed ID: 11395670
    [Abstract] [Full Text] [Related]

  • 10. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Dec 07; 11(6):1093-9. PubMed ID: 9663835
    [Abstract] [Full Text] [Related]

  • 11. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H, Yagi J, Komazawa Y, Mihara T, Katsube T, Fujishiro H, Shizuku T, Hattori S, Yamamoto S, Kinoshita Y.
    J Gastroenterol Hepatol; 2003 Dec 07; 18(12):1392-8. PubMed ID: 14675268
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS, Berardi RR.
    J Am Pharm Assoc (Wash); 2000 Dec 07; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [Abstract] [Full Text] [Related]

  • 13. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
    Adamek RJ, Behrendt J, Wenzel C.
    Eur J Gastroenterol Hepatol; 2001 Jul 07; 13(7):811-7. PubMed ID: 11474311
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.
    Van Rensburg CJ, Honiball PJ, Van Zyl JH, Grundling HD, Eloff FP, Spies SK, Simjee AE, Theron I, Fischer R, Louw JA.
    Aliment Pharmacol Ther; 1999 Aug 07; 13(8):1023-8. PubMed ID: 10468676
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
    Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van Milligen de Wit AW, de Groot GH, Dutch omeprazole MUPS study group.
    Eur J Gastroenterol Hepatol; 2002 Jun 07; 14(6):649-56. PubMed ID: 12072599
    [Abstract] [Full Text] [Related]

  • 16. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis.
    Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C.
    Aliment Pharmacol Ther; 1999 Nov 07; 13(11):1481-91. PubMed ID: 10571605
    [Abstract] [Full Text] [Related]

  • 17. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
    Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E.
    Aliment Pharmacol Ther; 1998 Jan 07; 12(1):49-52. PubMed ID: 9692700
    [Abstract] [Full Text] [Related]

  • 18. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
    Mössner J, Koop H, Porst H, Wübbolding H, Schneider A, Maier C.
    Aliment Pharmacol Ther; 1997 Dec 07; 11(6):1087-92. PubMed ID: 9663834
    [Abstract] [Full Text] [Related]

  • 19. [Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group].
    Gallo S, Dibildox M, Moguel A, Di Silvio M, Rodríguez F, Almaguer I, García C.
    Rev Gastroenterol Mex; 1998 Dec 07; 63(1):11-6. PubMed ID: 10068743
    [Abstract] [Full Text] [Related]

  • 20. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
    Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, Gatz G.
    Digestion; 2003 Dec 07; 67(1-2):6-13. PubMed ID: 12743434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.